RxDoctor Payments Data

Rafiullah Khan, MD

Hematology & Oncology · Cincinnati, OHNPI 1336304294

Payments from drug & device makers

$11,462in general payments, 2019–2025

Across 39 payments — averaging $293.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Beigene USA, Inc.$3K
  • Ipsen Biopharmaceuticals, Inc$2K
  • Incyte Corporation$2K
  • Sanofi$334
  • Bristol Myers Squibb$282
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$7,01561%
  • Speaking & faculty fees$1,72515%
  • Food & beverage$2,62723%
  • Education$951%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,462 in reported general payments places this provider in the 55th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,935,528
Medicare patients
380
Services billed
102,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide48$789,329
Lenalidomide48$446,660
PomalystPomalidomide22$403,471
CalquenceAcalabrutinib Maleate22$329,532
VenclextaVenetoclax16$183,046
PromactaEltrombopag Olamine13$175,460
Abiraterone Acetate51$118,909
EliquisApixaban93$110,701
SprycelDasatinib12$59,767
XareltoRivaroxaban44$48,426
Enoxaparin Sodium12$4,540
Acyclovir208$2,756
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,551
Potassium Chloride35$1,205
Hydroxyurea61$1,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$282$789,32948 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$254$463,23834 claims
AstraZenecaCalquence$3,348$329,53222 claims
AbbVieVenclexta$66$183,04616 claims
PfizerEliquis$13$110,70193 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →